Summary
This trial, executed by American researchers, aimed to assess associations between magnesium intake and prediabetes and/or diabetes-related symptoms (e.g., insulin resistance). The progression from these states to type 2 diabetes was also evaluated. 2582 participants, 26 to 81 years old at the start, were involved. This 7-year trial showed that participants with the highest magnesium intake had a 37% lower risk of impaired metabolic functions, such as increased fasting glucose levels and insulin resistance. Additionally, a higher intake was associated with a 32% lower risk of new-onset diabetes (individuals without diabetes at the beginning of the study) and impaired metabolic functions. In all participants, the risk of metabolic impairment in those with the highest intake was 53% of those with the lowest intake. Higher magnesium intake was associated with lower fasting glucose levels and insulin resistance (characteristics of diabetes type 2) at the end of the study. In conclusion, magnesium intake is beneficial in offsetting the risk of developing diabetes among those at high risk. More details can be found in the study.
References
Hruby et al.